Literature DB >> 28005607

Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study.

Anne-Marie Bouvier1, Nadine Bossard, Marc Colonna, Adelaida Garcia-Velasco, Maria Carulla, Sylvain Manfredi.   

Abstract

Pancreatic cancer represents a real clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from pancreatic cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These analyses were carried out using a flexible excess rate modelling strategy. There were little differences between countries in age-standardized net survivals (2000-2004). The 5-year net survival was poor (range: 6-10%). The changes in net survival from 1992 to 2004 were mostly related to early survival and patients aged 60 years. A slight decrease in the excess mortality rate between 1992 and 2004 was observed, limited to the 18 months after diagnosis. This study confirmed that, despite some improvement, survival from pancreatic cancer is still poor throughout European Latin countries. The major improvements in clinical imaging did not result in improvements in prognosis. Development of truly innovative treatments is highly needed to improve prognosis.

Entities:  

Mesh:

Year:  2017        PMID: 28005607     DOI: 10.1097/CEJ.0000000000000303

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  7 in total

1.  Retrospective cohort of pancreatic and Vater ampullary adenocarcinoma from a reference center in Mexico.

Authors:  Jorge Sánchez-García; Fernando Candanedo-González; Anna Karen Félix-Félix; Damián Sánchez-Ramírez; Rafael Medrano-Guzmán; Miguel Quintana-Quintana; Yair Benjamín Baas-Cabrera; Eugenia Flores-Figueroa
Journal:  Ann Med Surg (Lond)       Date:  2018-04-11

2.  Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.

Authors:  Ana Fernández; Mercedes Salgado; Adelaida García; Elvira Buxò; Ruth Vera; Jorge Adeva; Paula Jiménez-Fonseca; Guillermo Quintero; Cristina Llorca; Mamen Cañabate; Luis Jesús López; Andrés Muñoz; Patricia Ramírez; Paula González; Carlos López; Margarita Reboredo; Elena Gallardo; Manuel Sanchez-Cánovas; Javier Gallego; Carmen Guillén; Nuria Ruiz-Miravet; Víctor Navarro-Pérez; Juan De la Cámara; Inmaculada Alés-Díaz; Roberto Antonio Pazo-Cid; Alberto Carmona-Bayonas
Journal:  BMC Cancer       Date:  2018-11-29       Impact factor: 4.430

3.  Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study.

Authors:  Hongcheng Wang; Jiazhe Liu; Guanggai Xia; Shizhou Lei; Xiuyan Huang; Xinyu Huang
Journal:  Sci Rep       Date:  2020-04-27       Impact factor: 4.379

4.  ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer.

Authors:  Felipe A Calvo; Jose M Asencio; Falk Roeder; Robert Krempien; Philip Poortmans; Frank W Hensley; Marco Krengli
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-15

5.  Upregulated Apelin Signaling in Pancreatic Cancer Activates Oncogenic Signaling Pathways to Promote Tumor Development.

Authors:  Carline Chaves-Almagro; Johanna Auriau; Alizée Dortignac; Pascal Clerc; Hubert Lulka; Simon Deleruyelle; Fabrice Projetti; Jessica Nakhlé; Audrey Frances; Judit Berta; Véronique Gigoux; Daniel Fourmy; Marlène Dufresne; Anne Gomez-Brouchet; Julie Guillermet-Guibert; Pierre Cordelier; Bernard Knibiehler; Ralf Jockers; Philippe Valet; Yves Audigier; Bernard Masri
Journal:  Int J Mol Sci       Date:  2022-09-13       Impact factor: 6.208

6.  Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study.

Authors:  Adel Kardosh; Daphne Y Lichtensztajn; Matthew A Gubens; Pamela L Kunz; George A Fisher; Christina A Clarke
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.243

7.  Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging.

Authors:  Nicole Therville; Silvia Arcucci; Aurélie Vertut; Fernanda Ramos-Delgado; Dina Ferreira Da Mota; Marlène Dufresne; Céline Basset; Julie Guillermet-Guibert
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.